3-Chloropropyltrimethoxysilane (CPTMS) is a bifunctional organosilane that contains both a chloropropyl group and a trimethoxysilyl group. It is a colorless liquid with a pungent odor and is widely used as a coupling agent, adhesion promoter, and cross-linking agent in various industrial applications.
CPTMS is typically synthesized via a reaction between trichlorosilane and allyl alcohol, followed by chlorination of the resulting allyltrichlorosilane to produce 3-chloropropyltrichlorosilane. The final product is then obtained through a reaction with methanol.
The chloropropyl group of CPTMS can react with hydroxyl groups on surfaces, while the trimethoxysilyl group can hydrolyze and condense with itself or other silanes to form siloxane bonds. This bifunctional nature makes CPTMS an effective coupling agent, promoting adhesion between different materials, such as glass, metal, and polymers.
CPTMS is extensively studied due to its versatile applications in various fields. For example, it is used as a silane coupling agent in the production of composite materials, sealants, and adhesives. Its ability to improve the adhesion of coatings to substrates has made it a valuable component in paints, varnishes, and resins. Additionally, CPTMS is utilized in the synthesis of functionalized silica nanoparticles, which have applications in drug delivery, catalysis, and sensors.
CPTMS can be toxic and irritant, and proper handling and safety precautions are essential when working with this chemical. Its environmental impact is also a subject of research, as it can potentially degrade into harmful byproducts. However, its wide-ranging applications and unique properties have made it a valuable compound in various industrial sectors.'
| ID Source | ID |
|---|---|
| PubMed CID | 62449 |
| CHEMBL ID | 3184213 |
| SCHEMBL ID | 37352 |
| MeSH ID | M0546027 |
| Synonym |
|---|
| cps-m |
| kbm 703 |
| (gamma-chloropropyl)trimethoxysilane |
| 3-(trimethoxysilyl)propyl chloride |
| sila-ace s 620 |
| nsc 83878 |
| 3-chloropropyltrimethoxysilane |
| einecs 219-787-9 |
| sh 6076 |
| trimethoxy(3-chloropropyl)silane |
| gamma-chloropropyltrimethoxysilane , |
| LS-13231 |
| c6h15clo3si |
| AKOS008901063 |
| (3-chloropropyl)trimethoxysilan |
| NCIOPEN2_001219 |
| z 6076 |
| a 143 |
| 2530-87-2 |
| silane, (3-chloropropyl)trimethoxy- |
| silane (3-chloropropyl)tris(methoxy)- |
| .delta.-chloropropyltrimethoxysilane |
| nsc83878 |
| (.gamma.-chloropropyl)trimethoxysilane |
| nsc-83878 |
| .gamma.-chloropropyltrimethoxysilane |
| (3-chloropropyl)trimethoxysilane |
| 3-chloropropyltrimethyoxysilane |
| (3-chloropropyl)trimethoxysilane, >=97% |
| (3-chloropropyl)(trimethoxy)silane |
| 3-trimethoxysilylpropyl chloride |
| oxyzdrajmhgsmw-uhfffaoysa- |
| inchi=1/c6h15clo3si/c1-8-11(9-2,10-3)6-4-5-7/h4-6h2,1-3h3 |
| 3-chloropropyl-trimethoxysilane |
| 3-chloropropyl trimethoxysilane |
| 3-chloropropyl(trimethoxy)silane |
| NCGC00248491-01 |
| NCGC00257567-01 |
| cas-2530-87-2 |
| tox21_200013 |
| dtxcid207490 |
| dtxsid4027490 , |
| A817776 |
| ec 219-787-9 |
| unii-t21bnl1s7f |
| t21bnl1s7f , |
| FT-0604706 |
| S04675 |
| SCHEMBL37352 |
| cptmo |
| cl(ch2)3si(och3)3 |
| (ch3o)3si(ch2)3cl |
| chloropropyltrimethoxy-silane |
| chloropropyltrimethoxysilane |
| 3-trimethoxysilylpropylchloride |
| 3-chloropropyltrimethoxy silane |
| trimethoxysilylpropyl chloride |
| chloropropyl trimethoxysilane |
| petrarch c3300 |
| dow corning z-6076 |
| dynasylan cptmo |
| trimethoxy-(3-chloropropyl) silane |
| c 3300 |
| CHEMBL3184213 |
| mfcd00000997 |
| E77194 |
| (3-chloro-propyl)-trimethoxy-silane |
| Q27289563 |
| CS-0186811 |
| 163219-73-6 |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| AR protein | Homo sapiens (human) | Potency | 48.2542 | 0.0002 | 21.2231 | 8,912.5098 | AID743063 |
| thyroid hormone receptor beta isoform 2 | Rattus norvegicus (Norway rat) | Potency | 14.9928 | 0.0003 | 23.4451 | 159.6830 | AID743065; AID743067 |
| nuclear factor erythroid 2-related factor 2 isoform 1 | Homo sapiens (human) | Potency | 67.5447 | 0.0006 | 27.2152 | 1,122.0200 | AID743219 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (83.33) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.
| This Compound (35.24) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 6 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||